Previous studies by our group have shown that albumin is metabolized in rodents during renal passage and excreted in the urine as a mixture of intact protein and albumin-derived fragments. The aim of this study was to examine whether albumin is metabolized during renal passage in nondiabetic volunteers and in type 1 diabetic patients with varying levels of albuminuria. Nine nondiabetic normoalbuminuric volunteers and 11 type 1 diabetic patients with albumin excretion rates varying from normoalbuminuria to macroalbuminuria were studied. Each subject received an intravenous injection of tritium-labeled albumin ([ 3 H]-albumin). Urine was collected at 4 h and 24 h after injection and analyzed by size exclusion chromatography. The amount of intact and fragmented albumin was quantified, and each fraction was analyzed by radioimmunoassay (RIA) for albumin. [ 3 H]-albumin in nondiabetic volunteers was metabolized during renal passage to small peptide fragments not detectable by conventional RIA (only 0.05-3.8% of the total urinary radioactivity was associated with intact albumin). The process responsible for albumin fragmentation was similar in diabetic patients with normoalbuminuria (intact albumin represented 0.01-4.0% of total urinary radioactivity). However, there was a reduction in the fragmentation ratio (fragmented:intact) in diabetic patients with micro-or macroalbuminuria (intact albumin represented 2.7-55.5%, P = 0.048). This change in the fragmentation ratio was directly related to the degree of albuminuria. These results have important implications for understanding the mechanisms underlying albuminuria in nondiabetic volunteers and type 1 diabetic patients. In nondiabetic volunteers, the renal processing of albumin involves a relatively rapid and comprehensive degradation of albumin to small fragments (range 1-15 kDa). The degradation process is inhibited in diabetic nephropathy in proportion to the level of albuminuria detected by RIA. Diabetes 49:1579-1584, 2000 M icroalbuminuria, as measured by radioimmunoassay (RIA), is generally equated with the development of diabetic nephropathy in type 1 diabetes (1,2). The change in albumin excretion rate (AER) has traditionally been explained as being due to changes in the glomerular permselectivity barrier and intraglomerular pressure (3,4) with the assumption that albumin remains intact during filtration and renal passage. However, recent studies by our group using tritium-labeled albumin ([ 3 H]-albumin) in a rodent model have demonstrated that albumin excretion could be significantly influenced by the metabolism of albumin to small peptide fragments during its renal passage (5-9). The fragmentation is extensive, with 90-95% of the urinary albumin representing a complex fragment population of >30 different fragments with molecular weights in the range of 1-15 kDa. These albumin-derived fragments are not detected by standard immunochemical assays (6, 8) . A small number of studies have previously identified albumin fragments in human urine, although the source of these fragments has not been determined; these fragments (>15 kDa) were detected by electrophoretic immunochemical methods (10-12). In the streptozotocin-induced diabetic rat, we have demonstrated that the renal metabolism of albumin is partially inhibited, with a markedly different pattern of albumin fragments being excreted (8, 13) .
M icroalbuminuria, as measured by radioimmunoassay (RIA), is generally equated with the development of diabetic nephropathy in type 1 diabetes (1, 2) . The change in albumin excretion rate (AER) has traditionally been explained as being due to changes in the glomerular permselectivity barrier and intraglomerular pressure (3, 4) with the assumption that albumin remains intact during filtration and renal passage. However, recent studies by our group using tritium-labeled albumin ([ 3 H]-albumin) in a rodent model have demonstrated that albumin excretion could be significantly influenced by the metabolism of albumin to small peptide fragments during its renal passage (5) (6) (7) (8) (9) . The fragmentation is extensive, with 90-95% of the urinary albumin representing a complex fragment population of >30 different fragments with molecular weights in the range of 1-15 kDa. These albumin-derived fragments are not detected by standard immunochemical assays (6, 8) . A small number of studies have previously identified albumin fragments in human urine, although the source of these fragments has not been determined; these fragments (>15 kDa) were detected by electrophoretic immunochemical methods (10) (11) (12) . In the streptozotocin-induced diabetic rat, we have demonstrated that the renal metabolism of albumin is partially inhibited, with a markedly different pattern of albumin fragments being excreted (8, 13) .
The aim of this study was to examine whether [ 3 H]-albumin is metabolized during renal passage before excretion in nondiabetic volunteers and whether this process may change in type 1 diabetic patients with varying stages of diabetic nephropathy.
Patient selection criteria. Four groups of volunteer subjects of European origin were studied, as summarized in Table 1 . Type 1 diabetic patients were recruited from the diabetes clinic at the Austin & Repatriation Medical Center (A&RMC). Nondiabetic control volunteers were recruited at Monash University. All subjects were aged between 19 and 78 years. The groups were as follows:
• Group 1 (n = 9): nondiabetic volunteers with no history of diabetes or renal disease (normoalbuminuria) • Group 2 (n = 5): type 1 diabetic patients with AER <20 µg/min (normoalbuminuria) • Group 3 (n = 2): type 1 diabetic patients with AER between 20 and 200 µg/min (microalbuminuria) • Group 4 (n = 4): type 1 diabetic patients with AER >200 µg/min (macroalbuminuria) Tracer study. This study was approved by the A&RMC Human Ethics Committee and Radiation Safety Committee and was performed in the Nuclear Medicine Department of the A&RMC. Patients were screened for urinary tract infection by a Multistix dipstick test. The [ 3 H]-albumin was sterilized under aseptic conditions by passage through a 0.22-µm Millipore low protein binding sterilization filter before injection. A bolus injection of 1 mCi (~4 mg and 0.03 mSv) of ultrapure [ 3 H]-albumin was administered intravenously into a cubital vein. A small volume of blood was drawn from the contralateral arm after either 1 or 24 h after injection. Urine samples were collected at either 4 h after injection or 24 h after injection when another blood sample was taken.
The urine and plasma collected was fractionated by size exclusion chromatography using a Sephadex G-100 column (1.6 ϫ 60 cm 2 ) (Pharmacia Fine Chemicals, Uppsala, Sweden) eluted with PBS (which contained 0.2% bovine serum albumin and 0.02% sodium azide) at 20 ml/h at 4°C. One-milliliter samples were loaded, and 95 fractions of 1.7 ml each were collected. The void volume (V 0 ) was determined with blue dextran T2000 and the total volume (V t ) with tritiated water. The eluates were mixed with scintillant, and radioactivity was estimated using a scintillation counter and the amount of intact-to-fragmented albumin calculated from the area under the peaks.
Albumin concentration was measured by an in-house RIA (15) on the 24-h urine sample, whereas urinary creatinine was determined by the Jaffé method using the BM/Hitachi 737 automatic analyzer. All quantitative data are expressed as means ± SE, where n represents the number of determinations.
RESULTS
A representative elution profile from Sephadex G-100 of labeled fragments eluted before V t in the molecular weight range of 1-15 kDa. However, the elution profile of the plasma sample (1 h) reveals a small proportion (~ 1%) of labeled low-molecular weight material that elutes at the V t of the column. Similar amounts were also present in plasma collected 24 h after injection for all individuals used in this study. This finding indicates very low-molecular weight material (<1 kDa) that is likely to be free tritium. It is clear that the plasma material that elutes in the fraction-60 sample (representing 0.04% of the total plasma sample), corresponding to the maximum peak of the urine, would not contribute significantly to the material seen in the urine. In any case, results from rat studies have demonstrated that extrarenal albumin-derived fragments, if present in plasma, have very low fractional clearances because they avidly bind to plasma components (K.A. Greive, T.M.O., W.D.C., unpublished data). The very small quantity of low-molecular weight material in plasma that coelutes with urine fragments observed at any time collection together with their low fractional clearance effectively eliminates peripheral (extrarenal) metabolism of albumin contributing to the observed fragments in urine.
The presence of labeled low-molecular weight material in the urine profile was also not the result of degradation of albumin due to proteases in the urine because incubation of urine from a nondiabetic volunteer with [ degrees of albuminuria is shown in Fig. 4 . The profiles in Fig. 4 demonstrate that increased levels of albuminuria are associated with a marked change in the ratio of intact-to-fragmented albumin and that fragmentation of urinary albumin has been inhibited.
When the urine fractions from a macroalbuminuric patient were assayed for albumin by RIA, only the intact albumin peak was detected (Fig. 5) . This detection suggests that the RIA is specific for intact albumin and does not detect small albumin fragments. Thus, albumin concentration measured by RIA represents only intact albumin and considerably underestimates the combined total of intact albumin plus albuminderived fragments. We have previously shown that RIA measures only intact albumin for both bovine and rat albumin (6, 8) , where the presence of urinary albumin fragments was detected by both radioactivity and absorbance at 280 nm.
When the percentage of intact albumin, as determined by size exclusion chromatography, was plotted against the albumin-tocreatinine ratio for each subject (Fig. 6) , a significant relationship was found for the type 1 diabetic patients (r = 0.809, P < 0.0001). This finding is expected because albumin immunoassay measures only intact albumin. The percentage of intact albumin represented 1.29 ± 0.41% for nondiabetic volunteers, 1.36 ± 0.61% for normoalbuminuric type 1 diabetic patients, and 24.68 ± 9.21% for micro-and macroalbuminuric type 1 diabetic patients (P = 0.048 vs. normoalbuminuric patients).
DISCUSSION
A major finding reported in this study is that RIA detects only intact human albumin in urine. This result ensures that the percentage of intact albumin must increase with increasing albuminuria as measured by RIA; otherwise, if it remained constant at 1.29 ± 0.41%, the amount of total albumin (intact plus albumin-derived fragments) excreted would reach unrealistic levels (i.e., if the excretion rate by RIA is ~1,450 µg/min in a macroalbuminuric patient and this intact albumin is only ~1% of the total albumin excreted [intact plus fragments], then the total albumin excretion would be 145 mg/min). Studies of diabetic patients with increased levels of albuminuria demonstrated a significant correlation between the percentage of intact albumin and the level of albuminuria. This finding is also consistent with observations made in rats (6, 8) .
It is generally recognized that the metabolism of filtered proteins in the kidney occurs through lysosomal activity in proximal tubular cells (17, 18) . This study demonstrates that albumin in nondiabetic volunteers is metabolized to lowmolecular weight fragments during renal passage before excretion. These results are consistent with the findings obtained in rats (5) (6) (7) (8) (9) . The exact anatomical location of this metabolic degradation pathway is distal to the glomerular filtration barrier and is likely to occur by endocytosis and extensive lysosomal degradation in proximal tubule cells (17) . Once the fragments are formed in early endosomes or lysosomes, they may be returned to the tubular lumen with subsequent excretion in the urine within a matter of minutes. Proximal tubular cell endosomes associated with the gp330 albumin receptor have been recently shown to recycle back to the cell surface (19) . Furthermore, this type of metabolic degradation pathway has been observed in other studies that have demonstrated that protein may be taken up by lysosomes or cells in culture and returned to the medium as peptide fragments (20, 21) .
The fragmentation ratio (fragmented:intact) of albumin was reduced in diabetic patients; the magnitude of the reduction reflected an increase in (intact) albuminuria as determined by RIA. Our finding of a reduced fragmentation ratio of albumin in diabetes may correspond in part to decreased lysosomal activity and/or intracellular trafficking to and from the lysosome. This finding is consistent with findings in other studies that have shown that enzymes specifically associated with lysosomes have decreased activity in diabetes (22) (23) (24) . However, it is possible that this change in enzyme activity only affects the size of the fragments excreted and not the quantity. This study demonstrates that the capacity for albumin degradation during renal passage is significantly increased in diabetic subjects with increasing albuminuria, as is shown in Table 2 . The disorder of albumin processing as determined from albuminuric patients then relates to 2 distinct processes: 1) a decrease in the fragmentation ratio of albumin and 2) the increased capacity of renal cells to cope with the high flux of the albumin substrate. The absolute degradation rate appears to increase with higher albuminuria; therefore, the nephron cannot sustain a normal albumin excretion rate, and the system may be overwhelmed in albuminuric states.
The pathophysiological significance of these studies is that albuminuria may be influenced by intrarenal albumin metabolism. Intact albuminuria is not a true measure of total urinary albumin (intact albumin and albumin-derived fragments), and therefore caution must accompany the interpretation of changes in magnitude of this type of albuminuria as measured by RIA.
This study has identified albumin excretion rates (including albumin-derived fragments) to be much higher than those previously reported and demonstrated that this result is in part due to the high flux of albumin directed toward the metabolic degradation pathway. Recent studies have demonstrated that albumin flux across the glomerular capillary wall is normally high and that this albumin is retrieved by a cell- Data are means (range). Total albumin excretion rate = 100% ϫ AER/percent intact. Fragmented albumin excretion rate = total albumin excretion rate -AER retrieval pathway (25) that is distal to the glomerular filtration barrier. Inhibition of this pathway through blockage of intracellular trafficking/microtubule formation would potentially lead to these high fluxes of albumin. Other mechanisms that have been more widely discussed in the literature to explain the high flux of albumin to renal cells show that there may be a defect in the glomerular filtration barrier in diabetic nephropathy, allowing for increased filtration of serum proteins (3, 4) . However, the exact nature of this defect remains to be determined. It should be noted that previous glomerular models of albuminuria did not take into account the high excretion rate of albumin (intact plus fragments) that we identify in this study. Diabetes has been shown to be associated with the activation of protein kinase C (PKC) (26, 27) through angiotensin II binding to the type I angiotensin II receptor (28) . PKC effects on vesicular trafficking have been demonstrated to be a regulatory mechanism to control endocytosis and exocytosis of albumin in proximal tubular cells (29) . Protein kinases may contribute to regulation of proteins involved in microtubule-based motility or the cytoskeleton itself and thereby affect the associated transcellular passage of transport vesicles. Although the requirements for microtubular structures in transcytosis may not be homogeneous (30) , this kinase regulation might be a direct mechanism by which angiotensin II (through PKC and/or protein kinase A) could modulate the trafficking of albumin in epithelial cells of the nephron and lysosomal degradation (31, 32) .
We have established that the albumin-derived products present in urine from nondiabetic volunteers consist of a small amount of intact albumin together with a large quantity of albumin-derived fragments that are not detectable by conventional RIA. The reduced fragmentation ratio of albumin in diabetic patients with varying stages of nephropathy was found to be proportional to the level of albuminuria. The changes in the pattern of albumin fragments in the urine reflect a complex molecular processing of protein that appears to be impaired as nephropathy advances. This process may offer a new paradigm for the understanding of handling albumin in diabetic renal disease.
